Semler Scientific faced a challenging Q1 2025, posting a $64.7 million net loss largely due to a $29.8 million DOJ contingent liability and a $41.8 million unrealized loss on bitcoin holdings. Despite lower revenue year-over-year, the company expanded its bitcoin treasury and launched a public-facing bitcoin metrics dashboard.

Semler Scientific reported a transformative year in 2024, driven by its bitcoin treasury strategy. The company achieved strong financial performance in its healthcare business, with income from operations of $20.9 million for the full year. The strategic acquisition of 3,192 bitcoins, valued at approximately $300 million, significantly increased market capitalization by over 200% since May 2024.

Semler Scientific reported a decrease in revenue of 17% to $13.5 million, but net income increased by 2% to $5.6 million. The company's income from operations decreased by 20% to $5.1 million. The company purchased additional bitcoins, bringing its total holdings to 1,058.

Semler Scientific reported a decrease in revenue by 22% to $14.5 million and a net income of $11 thousand, a significant decrease compared to the previous year, primarily due to a $5.1 million negative change in the fair value of bitcoin holdings. Income from operations was $5.4 million, a decrease of 25%. The company continues to focus on acquiring and holding bitcoin while supporting its healthcare business.

Semler Scientific reported a decrease in revenue by 13% to $15.9 million, but net income increased by 22% to $6.1 million. The company had a strong quarter of cash generation despite the revenue decline. They are seeking a new 510(k) clearance from the FDA to market their heart dysfunction product, which they expect will re-accelerate revenues.

Semler Scientific reported Q4 2023 revenues of $15.1 million, a 9% increase year-over-year, and net income of $4.2 million, a 31% increase year-over-year. The company's cash balance increased to $57.3 million. They are seeking FDA clearance with expanded labeling for use as an aid in the diagnosis of other cardiovascular diseases.

Semler Scientific reported a 16% increase in revenue and a 50% increase in net income for the third quarter of 2023, driven by sales of QuantaFlo® for peripheral arterial disease testing. The company is focused on expanding its business in support of the diagnosis of heart dysfunction.

Semler Scientific reported a 25% increase in revenue to $18.6 million and a 44% increase in net income to $5.9 million for Q2 2023 compared to the corresponding period in 2022. The company achieved record quarterly revenues and pre-tax net income, primarily from sales of QuantaFlo®.

Semler Scientific reported a 30% increase in revenue, reaching $18.2 million, and a 48% increase in net income, amounting to $5.0 million for Q1 2023. The company's cash, cash equivalents, and short-term investments totaled $43.0 million.

Semler Scientific reported its Q3 2022 financial results, with revenue remaining unchanged at $14.0 million compared to the corresponding period of 2021. Net income was $3.7 million, a decrease of $0.5 million, or 11%, compared to $4.2 million. The company's cash and cash equivalents increased to $45.5 million.

Semler Scientific reported a 4% increase in revenue to $14.8 million and a net income of $4.1 million for Q2 2022. The company achieved record revenues and cash generation due to increased orders for QuantaFlo®.

Semler Scientific reported a revenue increase of 6% to $14.0 million and a net income of $3.4 million for the first quarter of 2022. The company's cash position increased, and a stock buyback program was initiated.

Semler Scientific reported a decrease in revenue and a significant decline in net income for Q4 2021 compared to Q4 2020. While fixed-fee license revenues increased, variable-fee license revenues and equipment/other sales decreased. The company experienced a COVID-19 related timing change in the home-testing market.

Semler Scientific reported a 30% increase in revenue for Q3 2021 compared to Q3 2020, reaching $14.0 million. However, net income decreased by 15% to $4.2 million, and diluted EPS decreased to $0.51.

Semler Scientific reported a strong second quarter with a 125% increase in revenues to $14.3 million compared to the same period last year. Net income increased by 522% to $6.7 million, or $0.83 per diluted share. The company's cash position strengthened to $28.5 million.

Semler Scientific reported a 40% increase in revenues to $13.2 million, a 74% increase in pre-tax net income to $6.0 million, and an 82% increase in net income to $4.9 million, or $0.73 per basic share and $0.60 per diluted share. The company's cash position also strengthened, reaching $26.5 million.

Semler Scientific reported strong financial results for Q4 2020, driven by the adoption of its QuantaFlo® product. The company saw increases in fixed fee software license revenues, variable fee software license revenues, and equipment/other sales.

Semler Scientific reported financial results for the three and nine months ended September 30, 2020. The company's financial performance rebounded from the effects of the COVID-19 pandemic.

Semler Scientific reported its Q2 2020 financial results, which were impacted by the COVID-19 pandemic. However, the company saw a recovery towards the end of the quarter as state governments eased restrictions. Variable fee license revenues increased in June compared to May, and preliminary results for July indicate further growth.

Semler Scientific reported their Q1 2020 financial results, noting the impact of COVID-19 late in the quarter. The company is managing expenses to preserve cash during the pandemic, with expectations of decreased operating expenses in Q2 2020 due to cost-cutting measures.

Semler Scientific reported financial results for the three months and year ended December 31, 2019, showing record performance.